Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study
is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic
SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).